Open AccessEffect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus
Author(s) -
Jong Suk Park,
Min Ho Cho,
Ji Sun Nam,
Jeong Seon Yoo,
Chul Woo Ahn,
Bong Soo,
Kyung Rae Kim,
Hyun Chul Lee
Publication year - 2010
Publication title -
european journal of endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.897
H-Index - 148
eISSN - 1479-683X
pISSN - 0804-4643
DOI - 10.1530/eje-10-0875
Subject(s) - pioglitazone , medicine , endocrinology , adiponectin , osteoprotegerin , insulin resistance , metformin , type 2 diabetes , type 2 diabetes mellitus , rosiglitazone , diabetes mellitus , receptor , activator (genetics)
Osteoprotegerin (OPG) acts as an important regulatory molecule in atherosclerosis. Recent studies report that thiazolidinediones could affect OPG expression. We investigated the relationship between OPG and inflammatory cytokines and the effects of pioglitazone (a PPARγ (PPARG) agonist) versus metformin on serum OPG levels in type 2 diabetic patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom